EP2391372A4 - Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition - Google Patents

Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition

Info

Publication number
EP2391372A4
EP2391372A4 EP10736464.8A EP10736464A EP2391372A4 EP 2391372 A4 EP2391372 A4 EP 2391372A4 EP 10736464 A EP10736464 A EP 10736464A EP 2391372 A4 EP2391372 A4 EP 2391372A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
methods
binding protein
estrogen receptor
positive cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10736464.8A
Other languages
German (de)
French (fr)
Other versions
EP2391372A1 (en
Inventor
David Kiewlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of EP2391372A1 publication Critical patent/EP2391372A1/en
Publication of EP2391372A4 publication Critical patent/EP2391372A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10736464.8A 2009-01-30 2010-01-29 Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition Withdrawn EP2391372A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14851809P 2009-01-30 2009-01-30
PCT/US2010/022552 WO2010088498A1 (en) 2009-01-30 2010-01-29 Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition

Publications (2)

Publication Number Publication Date
EP2391372A1 EP2391372A1 (en) 2011-12-07
EP2391372A4 true EP2391372A4 (en) 2013-07-03

Family

ID=42396035

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10736464.8A Withdrawn EP2391372A4 (en) 2009-01-30 2010-01-29 Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition

Country Status (3)

Country Link
EP (1) EP2391372A4 (en)
CA (1) CA2749947A1 (en)
WO (1) WO2010088498A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012013855A (en) 2010-05-28 2013-04-08 Univ Texas Oligo-benzamide compounds and their use.
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
GB201109965D0 (en) * 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
WO2013078288A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
ES2724300T3 (en) 2013-09-25 2019-09-10 Univ Cornell Compounds for inducing antitumor immunity and methods thereof
WO2020011909A1 (en) * 2018-07-11 2020-01-16 Secarna Pharmaceuticals Gmbh & Co. Kg Nucleic acid polymers inhibiting the expression of xbp1
WO2021119561A1 (en) * 2019-12-12 2021-06-17 University Of Maryland, Baltimore Inhibitors of cancer biomarkers and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020610A2 (en) * 2002-08-30 2004-03-11 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
WO2007101224A2 (en) * 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632608B2 (en) * 1999-12-30 2003-10-14 President And Fellows Of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
WO2002046467A2 (en) * 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2006108135A2 (en) * 2005-04-04 2006-10-12 Veridex, Llc Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020610A2 (en) * 2002-08-30 2004-03-11 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
WO2007101224A2 (en) * 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. P. GOMEZ ET AL: "Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines", THE FASEB JOURNAL, vol. 21, no. 14, 20 July 2007 (2007-07-20), pages 4013 - 4027, XP055061962, ISSN: 0892-6638, DOI: 10.1096/fj.06-7990com *
See also references of WO2010088498A1 *

Also Published As

Publication number Publication date
WO2010088498A1 (en) 2010-08-05
EP2391372A1 (en) 2011-12-07
CA2749947A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating dependence
EP2391372A4 (en) Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition
HK1209653A1 (en) Monoclonal antibodies for tumor treatment
IL197914A (en) Anti-ereg antibodies for treating cancer
IL219914A (en) 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
HK1173153A1 (en) Compounds useful for treating cancer
EP2558109A4 (en) Method for treating solid tumors
EP2252148A4 (en) Methods for treating bowel diseases
HK1131577A1 (en) Compositions for treating cancer
IL219331A0 (en) Method for treating androgrn receptor positive cancers
IL197633A0 (en) Methods for treating cancer with mva
EP2262366A4 (en) Compounds and methods for treating estrogen receptor-related diseases
ZA201203449B (en) Sulfoxide derivatives for treating tumors
ZA201003123B (en) Thiazol derivavtives for treating cancer
IL213398A0 (en) Compounds for treating cancer
EP2144888A4 (en) Methods for treating cancer
EP2029172A4 (en) Anti-c35 antibodies for treating cancer
PL2248115T3 (en) Adjusting drum for product-delivering spiral
PL2949361T3 (en) C-19 steroids for treating cellulite
HK1181642A1 (en) Method for treating liver disorders with receptor associated protein ( rap) peptide-fucosidase inhibitor conjugates (rap)-
PL2467140T3 (en) Lapatinib for treating cancer
EP2068911A4 (en) Methods for treating cancer
EP2281575A4 (en) Antibodies for treating cancer
EP2192904A4 (en) Methods for inhibiting tgf-
EP2307573A4 (en) Methods for screening for compounds for treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130603

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20130527BHEP

Ipc: A61K 31/7088 20060101ALI20130527BHEP

Ipc: A61K 31/00 20060101ALI20130527BHEP

Ipc: A61K 31/70 20060101AFI20130527BHEP

Ipc: A61K 39/395 20060101ALI20130527BHEP

Ipc: A61K 35/12 20060101ALI20130527BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130801